Prosecution Insights
Prosecution Insights
8 pending office actions • 2 clients • 7 examiners • 5 art units • 0 of 8 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| §102 only | 2 (25%) |
| §112 only | 1 (12%) |
| No statute on record | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 2 | 66.2% | -28.0% |
| SHERMAN, ERIC SCOTT | 1 | 72.2% | +14.6% |
| SCHUBERG, LAURA J | 1 | 23.9% | +37.3% |
| KIM, TAEYOON | 1 | 51.6% | +51.7% |
| JADHAO, SAMADHAN JAISING | 1 | 52.0% | +45.8% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.4% |
| MEJIAS, SAMANTHA LEE | 1 | 47.8% | +63.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18230278 | METHOD OF TREATMENT FOR HEART FAILURE USING STEM CELLS | SCHUBERG, LAURA J | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641787 | ANTI-NUCLEOLIN AGENT-PEG-CONJUGATED NANOPARTICLES | MEJIAS, SAMANTHA LEE | 3d overdue |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | KIM, TAEYOON | 12d |
| 17757599 | VIRUS-LIKE PARTICLE BINDING AGENTS, RELATED COMPOSITIONS, AND RELATED METHODS | JADHAO, SAMADHAN JAISING | 22d |
| 18230278 | METHOD OF TREATMENT FOR HEART FAILURE USING STEM CELLS | SCHUBERG, LAURA J | 34d |
| 18450060 | ULTRATHIN NANORIBBONS OF HIGHLY ANISOTROPIC LAYERED MATERIAL AND METHOD OF PRODUCTION | SHERMAN, ERIC SCOTT | — |
| 17741686 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | JONES, DAMERON LEVEST | — |
| Client (Assignee) | Pending OAs |
|---|---|
| UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 6 |
| Artios Pharma | 2 |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1631 | 2 |
| 1618 | 2 |
| 1736 | 1 |
| 1672 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18701664 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18450060 | ULTRATHIN NANORIBBONS OF HIGHLY ANISOTROPIC LAYERED MATERIAL AND METHOD OF PRODUCTION | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | SHERMAN, ERIC SCOTT | 1736 | §102 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18230278 | METHOD OF TREATMENT FOR HEART FAILURE USING STEM CELLS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 34d | Pending | Aug 04, 2023 |
| 18264079 | NOVEL PROCESS | Artios Pharma Limited | NOLAN, JASON MICHAEL | 1623 | Other | Non-Final OA | 30d overdue | Pending | Aug 03, 2023 |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | KIM, TAEYOON | 1631 | §103 | Final Rejection | 12d | Pending | Jul 12, 2022 |
| 17757599 | VIRUS-LIKE PARTICLE BINDING AGENTS, RELATED COMPOSITIONS, AND RELATED METHODS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | 22d | Pending | Jun 17, 2022 |
| 17741686 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | JONES, DAMERON LEVEST | 1618 | §102 | Final Rejection | — | Pending | May 11, 2022 |
| 17641787 | ANTI-NUCLEOLIN AGENT-PEG-CONJUGATED NANOPARTICLES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | MEJIAS, SAMANTHA LEE | 1618 | Other | Final Rejection | 3d overdue | Pending | Mar 09, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial